Amrubicin Doesn't Improve Overall Survival vs. Topotecan as Second-Line Treatment for Small-Cell Lung Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that amrubicin did not improve survival when compared to topotecan for the second-line treatment of patients with small-cell lung cancer (SCLC).
For the phase 3 study, 637 patients with refractory or sensitive SCLC were randomly assigned 2:1 to receive amrubicin, a third-generation anthracycline and topoisomerase II inhibitor, 40mg/m2 IV on days 1 through 3 or topotecan 1.5mg/m2 IV on days 1 through 5 of 21-day cycles.
Researchers found that amrubicin group had a median overall survival of 7.5 months versus 7.8 months in the topotecan group (HR, 0.880; P = 0.170). In patients with refractory SCLC, median overall survival was 6.2 months in the amrubicin group and 5.7 months in the topotecan group (HR, 0.88; P = 0.047). Median progression-free survival was 4.1 months and 3.5 for patients who received amrubicin and topotecan, respectively (HR, 0.802; P = 0.018).
Overall response rates were 31.1% for the amrubicin group and 16.9% for the topotecan group (OR, 2.223; P < 0.001). Despite positive results with amrubicin in SCLC in phase 2 trials, amrubicin did not improve overall survival when compared to topotecan; however, it did improve overall survival in patients with refractory disease.
Amrubicin did not improve survival when compared to topotecan for the second-line treatment of SCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma